Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

82.67 -0.65 (-0.78%)

Streaming Delayed Price Updated: 9:30 AM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 17, 2025

Via Benzinga

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

September 17, 2025

Via ACCESS Newswire

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

September 15, 2025

Via ACCESS Newswire

9 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗

June 03, 2025

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

September 12, 2025

Via Benzinga

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

September 11, 2025

Via ACCESS Newswire

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

August 26, 2025

Via ACCESS Newswire

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

August 25, 2025

Via ACCESS Newswire

What 4 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

August 07, 2025

Via Benzinga

Protagonist (PTGX) Q2 Revenue Falls 26% ↗

August 07, 2025

Via The Motley Fool

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 06, 2025

Via ACCESS Newswire

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

July 21, 2025

Via ACCESS Newswire

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

June 30, 2025

Via ACCESS Newswire

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

June 26, 2025

Via ACCESS Newswire

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 01, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

May 21, 2025

Via ACCESS Newswire

PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why. ↗

May 15, 2025

Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout.

Via Chartmill

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗

May 09, 2025

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Via Benzinga

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

May 09, 2025

Via ACCESS Newswire

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 06, 2025

Via ACCESS Newswire

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

April 23, 2025

Via ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Award

April 16, 2025

Via ACCESS Newswire

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study ↗

April 10, 2025

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Via Benzinga

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

April 10, 2025

Via ACCESS Newswire

Does PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) align with Mark Minervini’s trading strategy? ↗

April 05, 2025

Should you consider PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) for high growth investing? A fundamental and technical analysis of (NASDAQ:PTGX).

Via Chartmill

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

March 18, 2025

Via ACCESS Newswire

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.

Via Benzinga

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 11, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

All News about Protagonist Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today